[CAS NO. 2252262-24-9] Sabatolimab

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [2252262-24-9]

Catalog

HY-P99044

Brand

MCE

CAS

2252262-24-9

DESCRIPTION [2252262-24-9]

Overview

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Sabatolimab]

For research use only. We do not sell to patients.

Summary

Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3 , an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells ^[1] .

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04823624	Massachusetts General Hospital\|Novartis	Myelodysplastic Syndromes	September 2021	Phase 2
NCT04878432	Novartis Pharmaceuticals\|Novartis	Myelodysplastic Syndrome (MDS)	March 17, 2022	Phase 2
NCT03940352	Novartis Pharmaceuticals\|Novartis	Acute Myeloid Leukemia (AML)\|High-risk Myelodysplastic Syndrome (MDS)	June 24, 2019	Phase 1
NCT04810611	Novartis Pharmaceuticals\|Novartis	Myelodysplastic Syndromes	June 18, 2021	Phase 1
NCT05201066	Novartis Pharmaceuticals\|Novartis	Myelodysplastic Syndromes\|Leukemia, Myelomonocytic, Chronic	January 2, 2023	Phase 2
NCT04266301	Novartis Pharmaceuticals\|Novartis	Myelodysplastic Syndromes\|Leukemia, Myelomonocytic, Chronic	June 8, 2020	Phase 3
NCT03066648	Novartis Pharmaceuticals\|Novartis	Leukemia\|Leukemia, Myeloid\|Leukemia, Myeloid, Acute\|Myelodysplastic Syndromes\|Preleukemia\|Bone Marrow Diseases\|Hematologic Diseases\|Chronic Myelomonocytic Leukemia	July 6, 2017	Phase 1
NCT04623216	Novartis Pharmaceuticals\|Novartis	Acute Myeloid Leukemia	September 14, 2021	Phase 1\|Phase 2
NCT03946670	Novartis Pharmaceuticals\|Novartis	Myelodysplastic Syndromes	June 4, 2019	Phase 2
NCT02608268	Novartis Pharmaceuticals\|Novartis	Advanced Malignancies	November 23, 2015	Phase 1\|Phase 2
NCT04150029	Novartis Pharmaceuticals\|Novartis	Acute Myeloid Leukemia	September 1, 2020	Phase 2
NCT05367401	Novartis Pharmaceuticals\|Novartis	Myelodysplastic Syndromes\|Acute Myeloid Leukemia	December 20, 2024	Phase 1\|Phase 2
NCT04097821	Novartis Pharmaceuticals\|Novartis	Myelofibrosis	September 26, 2019	Phase 1\|Phase 2
NCT04812548	Novartis Pharmaceuticals\|Novartis	Myelodysplastic Syndrome (MDS)	May 31, 2021	Phase 2
NCT03961971	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Novartis Pharmaceuticals	Glioblastoma Multiforme	February 18, 2020	Phase 1
NCT04283526	Novartis Pharmaceuticals\|Novartis	Primary Myelofibrosis\|Myelofibrosis\|PMF\|Post-Essential Thrombocythemia Myelofibrosis\|Post-Polycythemia Vera Myelofibrosis	November 30, 2020	Phase 1

Appearance

Liquid

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] Andrew M. Brunner, et al. Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study. B